Samir Khleif
Corporate Officer/Principal chez INTELLIGENT MEDICINE ACQUISITION CORP.
Fortune : 32 $ au 30/04/2024
Profil
Samir N.
Khleif is the founder of Georgiamune, Inc. He currently holds multiple positions including Chief Executive Officer at King Hussein Cancer Center, Director at Augusta University, Director at Georgia Cancer Center, Venture Advisor at Israel Biotech Fund, and Advisor at Intelligent Medicine Acquisition Corp.
Previously, he served as an Independent Director at Advaxis, Inc., Director at Ayala Pharmaceuticals, Inc., and Chief-Cancer Vaccine Section at National Cancer Institute.
Khleif received his undergraduate degree from Augusta University and his graduate degree from the University of Jordan Medical School in 1986.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/12/2022 | 59 ( 0,00% ) | 32 $ | 30/04/2024 |
Postes actifs de Samir Khleif
| Sociétés | Poste | Début |
|---|---|---|
| INTELLIGENT MEDICINE ACQUISITION CORP. | Corporate Officer/Principal | - |
| Augusta University | Directeur/Membre du Conseil | - |
| Georgia Cancer Center | Directeur/Membre du Conseil | - |
Georgiamune, Inc.
 Georgiamune, Inc. BiotechnologyHealth Technology Georgiamune, Inc. is a clinical stage biotechnology company that focuses on reprogramming immune signaling pathways to redirect the immune system to fight diseases. The company is based in Silver Spring, MD. The company has designed unique approaches to re-establish immune balance, and its scientific discoveries have led to pioneering immunotherapies targeting high unmet needs. Georgiamune's lead program, Gim-122, is a first-in-class, dual-functioning monoclonal antibody designed to overcome immune therapy resistance in cancer patients. In addition to its lead program, the company is advancing a pipeline of first-in-class therapies for cancer and autoimmune diseases. The company was founded by Samir N. Khleif, a world-renowned medical oncologist and researcher in the field of immunology and cancer, based on discoveries in his lab on novel mechanisms to modulate immune response. Samir N. Khleif has been the CEO since incorporation. | Directeur Général | - |
| King Hussein Cancer Center | Directeur Général | - |
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Consultant / Advisor | - |
Anciens postes connus de Samir Khleif
| Sociétés | Poste | Fin |
|---|---|---|
| AYALA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 19/10/2023 |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
| AYALA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | - |
Formation de Samir Khleif
| Augusta University | Undergraduate Degree |
| University of Jordan Medical School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AYALA PHARMACEUTICALS, INC. | Commercial Services |
| Entreprise privées | 7 |
|---|---|
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
| King Hussein Cancer Center | |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
| Georgia Cancer Center | |
Georgiamune, Inc.
Georgiamune, Inc. BiotechnologyHealth Technology Georgiamune, Inc. is a clinical stage biotechnology company that focuses on reprogramming immune signaling pathways to redirect the immune system to fight diseases. The company is based in Silver Spring, MD. The company has designed unique approaches to re-establish immune balance, and its scientific discoveries have led to pioneering immunotherapies targeting high unmet needs. Georgiamune's lead program, Gim-122, is a first-in-class, dual-functioning monoclonal antibody designed to overcome immune therapy resistance in cancer patients. In addition to its lead program, the company is advancing a pipeline of first-in-class therapies for cancer and autoimmune diseases. The company was founded by Samir N. Khleif, a world-renowned medical oncologist and researcher in the field of immunology and cancer, based on discoveries in his lab on novel mechanisms to modulate immune response. Samir N. Khleif has been the CEO since incorporation. | Health Technology |
Intelligent Medicine Acquisition Corp.
 Intelligent Medicine Acquisition Corp. Electrical ProductsProducer Manufacturing Intelligent Medicine Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Bethesda, MD. | Producer Manufacturing |
